Novavax Covid-19 vaccine receives Australian TGA approval for adolescents
The approval is based on findings from the paediatric expansion of the Phase III PREVENT-19 trial underway in the US.

The approval is based on findings from the paediatric expansion of the Phase III PREVENT-19 trial underway in the US.
In Phase II/III KidCOVE trial, the vaccine offered a strong neutralising antibody response in children.
The latest provisional registration is based on findings from two Phase II trials and the COV-BOOST trial of the vaccine.
The Australian TGA had granted provisional registration for the vaccine use in adult individuals in August last year.
Australia’s health minister said Novavax’s coronavirus jab, Nuvaxovid, should be available from February 21.
ByThe medications are the first oral treatments for Covid-19 to be approved in the country.
The company will collaborate with the University of NSW and Macquarie University for vaccine development.
On acquisition, the merged company will have a pipeline of 37 products at various stages of development.
Thank you for subscribing to Pharmaceutical Technology